United States Patent 7,405,203: Scope, Claim Boundaries, and Landscape

US Drug Patent 7,405,203 is directed to methods using desmopressin with tightly bounded systemic exposure. The claims define (i) indication (nocturia, primary nocturnal enuresis, incontinence, voiding postponement; plus antidiuretic effect), (ii) route options (transmucosal, transdermal, intradermal; and several claims add IV and subcutaneous), and (iii) pharmacokinetic control via maximum and maintained plasma/serum concentration windows (upper bound ≤10 pg/mL, maintained around 0.5 to 10 pg/mL for ~4 to 6 hours, with narrower fall-backs such as ≤5 pg/mL and ranges above 0.1 pg/mL).

This is a dose-exposure-defined patent: the actionable scope is determined less by formulation name and more by whether a competitor’s method produces the required Cmax and time-above-threshold/exposure duration.

What is claimed, in patent-claim terms?

Core independent claim structure

From the claim set provided, the central concept is:

Treat or induce antidiuretic effect by administering a desmopressin pharmaceutical composition
Achieve a maximum desmopressin plasma/serum concentration (Cmax) ≤ 10 pg/mL
Maintain systemic concentration within about 0.5 pg/mL to 10 pg/mL for about 4 to 6 hours
Use one or more delivery routes depending on the dependent claim

This combination (exposure ceiling + maintained window + time) forms the literal infringement fence.

Claim-by-claim scope mapping (provided claims)

The following table converts the provided claims into “infringement elements” language.

Claim	Method purpose	Desmopressin exposure limitation	Delivery routes explicitly covered	Time/threshold limitation
1	Treat nocturia / primary nocturnal enuresis / incontinence or induce voiding postponement	Cmax ≤ 10 pg/mL and concentration maintained ~0.5 to 10 pg/mL	Any route in claim 1 base (delivery route appears in dependent claims)	~4 to 6 hours maintained
2	Same as claim 1	Same as claim 1	Transmucosal, transdermal, intradermal	Same as claim 1
3	Treat nocturia	Same as claim 1	Not limited in claim 3 itself (but claim 3 depends on claim 1)	Same as claim 1
4	Same as claim 1	Same as claim 1	Intravenous	Same as claim 1
5	Same as claim 1	Same as claim 1	Subcutaneous	Same as claim 1
6	Same as claim 1	Same as claim 1	Transmucosal	Same as claim 1
7	Same as claim 1	Same as claim 1	Transdermal	Same as claim 1
8	Same as claim 1	Same as claim 1	Intradermal	Same as claim 1
9	Same as claim 1	Narrower: maintained ≤ about 5 pg/mL	Same as claim 1 (inherited)	Same 4 to 6 hours
10	Induce an antidiuretic effect	Cmax ≤ 10 pg/mL	Transmucosal, transdermal, intradermal	“amount and time sufficient” to establish Cmax ceiling
11	Same as claim 10	Same as claim 10	Same as claim 10 (inherited)	Indication: incontinence, PNE, nocturia
12	Same as claim 10	Narrower: Cmax ≤ about 5 pg/mL	Same as claim 10	“amount and time sufficient”
13	Treat nocturia	0.1 pg/mL < Cmax < 10 pg/mL	Transmucosal, transdermal, intradermal	Maintained >0.1 pg/mL for >4 hours (via claim 15)
14	Same as claim 13	Same as claim 13	Same as claim 13	Patient: human or other mammal
15	Enforces exposure persistence	Concentration >0.1 pg/mL	Same as claim 13	time greater than 4 hours

Key claim boundaries that determine infringement

Cmax ceiling: ≤10 pg/mL
The method must produce a maximum plasma/serum desmopressin concentration at or below 10 pg/mL for the claimed method versions.
Maintained exposure window (claim 1)
Claim 1 adds a temporal constraint: concentration maintained within about 0.5 to 10 pg/mL for about 4 to 6 hours. This is more specific than a mere Cmax requirement.
Route-dependent claim sets
- Claims 2, 6, 7, 8, 10, 11, 13, 15 cover transmucosal/transdermal/intradermal routes.
- Claims 4 and 5 cover IV and subcutaneous. This matters because a competitor using a different delivery route could attempt design-around if their route falls outside certain dependents, while still risking broader independent coverage (depending on how “delivery route” is treated in claim 1’s wording).
Narrow “≤5 pg/mL” fall-backs (claims 9 and 12)
These dependents narrow the ceiling. A competitor achieving Cmax between 5 and 10 pg/mL may still fall within claim 1/10/13 but not within 9/12.
Lower bound for “nocturia” in claims 13 and 15
Claim 13 does not just cap at 10 pg/mL; it also requires greater than 0.1 pg/mL and less than 10 pg/mL. Claim 15 adds persistence: concentration >0.1 pg/mL for more than 4 hours. This is a guardrail against trivial exposure.

How do the claims read as “scope” for product and clinical execution?

Practical infringement test: PK outcomes, not just administration

Because the claims are written as “administering … comprising a dose … sufficient to achieve” specific plasma/serum concentration patterns, infringement analysis typically turns on:

dosing regimen,
sampling timepoints used to determine the measured Cmax,
whether concentration is within the stated range for the stated duration (claim 1),
whether concentration is maintained above 0.1 pg/mL for >4 hours (claims 13 and 15).

The most risk-sensitive elements

For a competitor targeting nocturia or enuresis with low-dose desmopressin exposure, the highest-risk elements are:

Cmax target at or below 10 pg/mL while staying high enough to clear the lower bounds where required (notably claims 13/15),
duration of exposure (4 to 6 hours for claim 1; >4 hours for claim 15).

A product that yields Cmax under 10 pg/mL but drops below required thresholds too quickly could avoid some claim types, even if it still “treats” nocturia, because the claims explicitly constrain exposure time.

Does the patent cover formulations or only dosing regimens?

On the face of the claim text provided, the patent does not appear to be limited to a particular formulation chemistry or device. The method includes a “pharmaceutical composition comprising desmopressin,” but the patent’s operative novelty is expressed via:

dose sufficiency to obtain certain Cmax values, and
maintenance of concentrations within specified ranges for specified time windows,
combined with selected routes.

That makes the scope regimen-centric: a competitor formulation is within scope if it produces the required systemic exposure profile via one of the claimed routes and achieves the claimed clinical method purpose.

What is the likely defensible “design-around” space?

Based on the claim structure, the main design-around levers are:

Shift Cmax outside the bounds
- Avoid producing Cmax ≤10 pg/mL for claim 1/10/13, or
- For nocturia versions that require 0.1 < Cmax < 10, avoid the lower bound (≤0.1 pg/mL) or raise above 10 pg/mL (while still treating clinically).
Fail the exposure duration constraint
- Claim 1 requires maintained concentration in ~0.5 to 10 pg/mL for ~4 to 6 hours.
- Claim 15 requires >0.1 pg/mL for >4 hours. A regimen that produces the right Cmax but falls below thresholds earlier can reduce literal risk.
Use delivery routes not covered by the relevant dependents The dependents cover transmucosal, transdermal, intradermal, IV, and subcutaneous routes. The claim set provided does not list, for example, oral routes, buccal-specific language beyond transmucosal, or inhalational routes. If a competitor uses a route not encompassed by claim language, risk depends on how broadly claim 1 is construed regarding delivery route.

Competitive and regulatory context: what “space” does it target?

The clinical framing (nocturia, enuresis, incontinence, voiding postponement) aligns with desmopressin’s antidiuretic role. The PK specificity suggests the patent is intended to enable treatment with lower systemic exposure while still achieving an antidiuretic effect for a time sufficient to reduce nighttime voiding events.

This is consistent with the concept that adverse effects correlate with higher systemic exposure and that limiting exposure can improve tolerability. The patent’s claim language builds that into the method itself.

What does the patent landscape likely look like around it (US market + desmopressin delivery IP)?

How to read the landscape using this patent’s claim pattern

Even without listing every single adjacent application, the landscape around desmopressin in nocturia typically clusters by:

routes (intranasal historically; transmucosal; transdermal; intradermal; injection),
dose selection and patient timing (nighttime dosing regimens),
PK targets (Cmax ceilings, duration windows),
device/formulation (sprays, patches, microneedles/ID delivery, solubilization tech),
indications (nocturia, PNE, enuresis, incontinence).

US 7,405,203’s distinguishing feature is the use of low pg/mL PK ceilings and persistence windows as the legal hook. Adjacent patents often try to claim either:

a different route/formulation combination, or
a different PK target (different Cmax thresholds and/or different time windows), or
a different indication claim set (e.g., nocturia vs enuresis vs general antidiuretic effect).

Most relevant “overlap” risk categories

For a company developing low systemic exposure desmopressin for nighttime indications, the overlap risk typically concentrates in three areas:

Low-exposure transdermal/transmucosal desmopressin regimens for nocturia/PNE/incontinence
Claim 2, 6, 7, 8, 10, 11, 13, 15 show the patent explicitly covers these routes when the PK profile is within defined bounds.
Combination of antidiuretic effect framing with PK ceilings
Claims 10 to 12 cover inducing an antidiuretic effect with Cmax ≤10 pg/mL (and ≤5 pg/mL in claim 12).
Injection routes still captured
Claims 4 and 5 include IV and subcutaneous administration under claim 1’s PK windows, reducing the safe harbor for injected alternatives if they match the exposure profile.

What is the scope of legal “claim coverage” for downstream development?

For a development program, US 7,405,203 creates two key constraints:

If your product matches the targeted PK profile, route and indication become secondary If your regimen achieves the required Cmax ≤10 pg/mL and, for the relevant claim set, matches the duration and lower bound constraints, you can fall within scope even if your formulation technology differs.
If your program changes only the formulation or device without moving PK outcomes, you may not escape The claims are not framed as “using formulation X.” They are framed as “administering a composition such that concentration achieves Y.” That puts emphasis on PK equivalence rather than ingredient identity alone.

Key Takeaways

US 7,405,203 is a PK-defined desmopressin method patent with legal scope anchored to Cmax ceilings (≤10 pg/mL; ≤5 pg/mL in narrower dependents) and time-based maintained exposure (notably ~4 to 6 hours and >4 hours above 0.1 pg/mL).
It covers methods for nocturia, primary nocturnal enuresis, incontinence, voiding postponement, and inducing an antidiuretic effect.
Route coverage spans transmucosal, transdermal, intradermal, and also intravenous and subcutaneous under dependent claims.
The most actionable infringement risk turns on whether your regimen produces the claimed plasma/serum concentration profile for the required duration, not on device naming or formulation marketing.

FAQs

1) What measurement drives infringement risk in US 7,405,203?

Plasma/serum desmopressin concentration, specifically Cmax and whether concentrations fall within the stated ranges for the stated time windows (e.g., ~0.5 to 10 pg/mL for ~4 to 6 hours in claim 1; >0.1 pg/mL for >4 hours in claim 15).

2) Does the patent require a particular desmopressin form (chemical variant) in the provided claims?

The provided claims require “desmopressin” in a pharmaceutical composition, but they do not specify a particular salt or formulation type in the claim text shown. The binding constraint is the achieved systemic concentration profile.

3) If a regimen treats nocturia but has Cmax above 10 pg/mL, is it within the provided claims?

Claim 1 requires Cmax no greater than 10 pg/mL; claim 13 requires Cmax greater than 0.1 pg/mL and less than 10 pg/mL. A Cmax above 10 pg/mL does not satisfy those literal thresholds.

4) Are transdermal and intradermal routes explicitly covered?

Yes. Claims 7 and 8 cover transdermal and intradermal administration (as dependents of claim 1). Claims 10 and 13 also cover transmucosal/transdermal/intradermal delivery.

5) What is the scope difference between claim 1 and claim 10?

Claim 1 ties treatment of nocturia/PNE/incontinence/voiding postponement to both Cmax ≤10 pg/mL and maintained concentration within ~0.5 to 10 pg/mL for ~4 to 6 hours. Claim 10 ties inducing an antidiuretic effect to Cmax ≤10 pg/mL via transmucosal/transdermal/intradermal delivery, with the time captured indirectly (“amount and for a time sufficient to establish” the Cmax ceiling).

References

[1] United States Patent No. 7,405,203 (claim text provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	039092	⤷ Start Trial
Argentina	039794	⤷ Start Trial
Argentina	107948	⤷ Start Trial
Austria	333886	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,405,203

Summary for Patent: 7,405,203